Immunoprophylactic effects of the anti-leprosy Mw vaccine in household contacts of leprosy patients: Clinical field trials with a follow up of 8-10 years

Leprosy Review

Volumn 76, Issue 2, 2005, Pages 127-143

  Sharma, Pankaj ^a   Mukherjee, Rama ^a,f   Talwar, G P ^a,g   Sarathchandra, K G ^a   Walia, R ^a   Parida, S K ^a,i   Pandey, R M ^a,h   Rani, Rajni ^a   Kar, Hemant ^b   Mukherjee, Ashok ^c   Katoch, Kiran ^d   Benara, S K ^e   Tulsi, ^e   Singh, Padam ^e  

^a NATIONAL INSTITUTE OF IMMUNOLOGY   (India)

^b DR RAM MANOHAR LOHIA HOSPITAL   (India)

^c SAFDARJUNG HOSPITAL   (India)

^d NATIONAL JALMA INSTITUTE FOR LEPROSY AND OTHER MYCOBACTERIAL DISEASES   (India)

^e INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

^f DABUR RESEARCH FOUNDATION   (India)

^g Talwar Research Foundation   (India)

^h ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

ⁱ UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MYCOBACTERIUM VACCINE; MYCOBACTERIUM W VACCINE; PLACEBO; TETANUS TOXOID; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; CHILD; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HOUSEHOLD; HUMAN; IMMUNOPROPHYLAXIS; LEPROSY; MAJOR CLINICAL STUDY; MALE; MULTIBACILLARY LEPROSY; MULTIPLE DRUG DOSE; PAUCIBACILLARY LEPROSY;

ADOLESCENT; ADULT; AGED; BACTERIAL VACCINES; CHILD; CHILD, PRESCHOOL; DISEASE TRANSMISSION, HORIZONTAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FAMILY CHARACTERISTICS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDIA; LEPROSY; MALE; MIDDLE AGED; PROBABILITY; REFERENCE VALUES; RISK ASSESSMENT; TIME FACTORS; VACCINATION;

EID: 22844441049     PISSN: 03057518     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (30)

1. De Sarkar A, Kaur I, Radotra BD, Kumar B. Impact of combined Mycobacterium w vaccine and 1 year MDT on multibacillary leprosy patients. Int J Lepr other Mycobact Dis, 2000; 69: 187-194.
2. Katoch K, Katoch VM, Natrajan M et al. Treatment of bacilliferous BL/LL cases with combined chemotherapy and immunotherapy. Int J Lepr other Mycobact Dis, 1995; 63: 202-212.
3. Sharma P, Misra RS, Kar HK et al. Mycobacterium w vaccine, a useful adjuvant to multidrug therapy in multibacillary leprosy: a report on hospital based trials with a follow-up of 1-7 years after treatment. Lepr Rev, 2000; 71: 179-192.
4. Talwar GP, Mukherjee R, Zaheer SA et al. Present approaches to immunotherapy and immunoprophylaxis in leprosy. In: Talwar GP (ed) Progress in Vaccinology, vol. II. Springer-Verlag, New York, 1989, pp. 301-311.
5. Talwar GP, Zaheer SA, Mukherjee R et al. Immunotherapeutic effects of a vaccine based on a saprophytic cultivable mycobacterium, Mycobacterium w, in multibacillary leprosy patients. Vaccine, 1990; 8: 121-129.
6. Mittal BN. The national leprosy eradication programme in India. World Health Sta. Q, 1991; 44: 23-29.
7. National Leprosy Eradication Programme in India. Guidelines for modified MDT scheme in selected districts Leprosy Division, Directorate General of Health Services, Ministry of Health Welfare, New Delhi 1990.
8. WHO Expert Committee on Leprosy. World Health Organ Tech Rep Ser, 1988; 768: 1-51.
9. Ornestein WA, Bernier RH, Dondero TJ et al. Field evaluation of vaccine efficacy. Bull Wld Hlth Org, 1985; 63: 1055-1068.
10. Walia R, Sarathchandra KG, Pandey RM et al. Field trials on the use of Mycobacterium w vaccine in conjunction with multi drug therapy in leprosy patients for immunotherapeutic and immunoprophylactic purposes. Lep Rev, 1993; 64: 302-311.
11. Fine PE. South Indian leprosy vaccine trial: important lessons for mycobacterial immunology. Lepr Rev, 1999; 70: 247-249.
12. Sharma P, Kar HK, Kaur H et al. Induction of lepromin positivity and immunoprophylaxix in household contacts of multibacillary leprosy patients: a Pilot study with a candidate vaccine Mycobacterium w. Int J Lepr, 2000; 68: 136-142.
13. Gupte MD, Vallishayee RS, Anantharaman DS et al. Comparative leprosy vaccine trail in South India. Ind J Lepr, 1998; 70: 369-388.
14. Chaterjee KR, Soucou P, Sainte-Rose M. Prophylactic value of BCG vaccination against leprosy: a preliminary report. Bull Calcutta Sch Trop Med, 1958; 6: 164-166.
15. Convit J. Studies on leprosy in the German ethnic group of Colonia Tovar, Venezuela, Morbidity rates in BCG vaccinated and unvaccinated group during five years. Int J Lepr, 1956; 24: 269-275.
16. Fernandez J. Influence of the tuberculosis factor on the clinical and immunological evolution of child contacts with leprosy patients. Int J Lepr, 1953; 23: 243-258.
17. Yanagisawa K. On the immunological relationship between tuberculosis and leprosy with special reference to the effect of BCG administration upon the prophylaxis of leprosy. La Le pro, 1970; 26: 37-47.
18. Gupte MD. Field trials of anti-leprosy vaccine. Ind J Lepr, 1998; 70: 363-365.
19. Abel L, Cua VV, Oberti J et al. Leprosy and BCG in Southern Vietnam (Letter). Lancet, 1990; 335: 1536.
20. Bagashawe A, Scot GC, Russel DA et al. BCG vaccination in leprosy: final results of the trial in Karimui Papua New Guinea, 1963-79. Bull WHO, 1989; 67: 389-399.
21. Baker DM, Nguyen-Van-Tam JS, Smith SJ. Protective efficacy of BCG vaccine against leprosy in Southern Malawi. Epidemiol Infect, 1993; 111: 21-25.
22. Bechelli LM, Garbajosa G, Uemura K et al. BCG vaccination of children against leprosy: preliminary findings of the WHO-controlled trial in Burma. Bull Wld Hlth Org, 1970; 42: 235-281.
23. Convit J, Smith PG, Zuniga M et al. BCG vaccination protects against leprosy in Venezuela: a case control study. Int J Lepr other Mycobact Dis, 1993; 61: 185-191.
24. Rodrigues MLO, Silva SA, Neto JCA et al. Protective effect of intradermal BCG against leprosy: a Case-control study in Central Brazil. Int J Lepr, 1992; 60: 335-339.
25. Fine PEM, Ponnighaus JM, Maine N et al. Protective efficcay of BCG against leprosy in Northern Malawi. Lancet, 1986; 2: 409-502.
26. Kinnear Brown JA, Mary Stone M, Sutherland I. Trial of BCG vaccination against leprosy in Uganda. Lepr Rev, 1969; 40: 3-7.
27. Mulyil J, Nelson KE, Diamond EL. Effect of BCG on the risk of leprosy in an endemic area: a case-control study. Int J Lepr, 1991; 59: 229-236.
28. Convit J, Sampson C, Zuniga M et al. Immunoprophylactic trial with combined Mycobacterium leprae/BCG vaccine against leprosy: preliminary results. Lancet, 1992; 339: 446-450.
29. Gupte MD. South India immunoprophylactic trial against leprosy: relevance of the findings in the context of trends in leprosy. Lepr Rev, 2000; 71s: s43-s49.
30. Britton WJ, Martin E, Kamath AT et al. Immunoprophylaxis against Mycobacterium leprae infection with subunit vaccines. Lepr Rev, 2000; 71s: s176-s181.